6-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                    -----------------------------------------


                                    FORM 6-K


                        Report of Foreign Private Issuer
                        Pursuant to Rule 13a-16 or 15d-16
                        of the Securities Exchange Act of
                                      1934


                          For the month of March, 2002


                              HAEMACURE CORPORATION
             (Exact name of Registrant as specified in its charter)


                                 Not Applicable
                  (Translation of registrant's name in English)


                                     Canada
                 (Jurisdiction of incorporation or organization)

                           2001 University, Suite 430
                         Montreal, Quebec H3A 2A6 CANADA
          (Address of principal executive offices, including zip code)


[Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F]

                     Form 20-F  X        Form 40-F
                               ---                 ---

[Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934]

                     Yes                 No  X
                        ---                 ---

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
N/A





                              HAEMACURE CORPORATION



FORM 6-K:  TABLE OF CONTENTS

EXHIBITS

Exhibit 99.1    Press Release of Haemacure Corporation, dated March 13, 2002,
                regarding manufacturing of the Hemaseel HMN product








                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                        HAEMACURE CORPORATION


                                        By: /s/ Gilles Lemieux
                                           -------------------------------------
                                           Name:  Gilles Lemieux
                                           Title: Secretary


                              Date: March 22, 2002






                                  EXHIBIT INDEX


Exhibit 99.1     Press Release of Haemacure Corporation, dated March 13, 2002,
                 regarding manufacturing of the Hemaseel HMN product.

EX-99.1

                             HAEMACURE CORPORATION

                                                           For immediate release

                                  PRESS RELEASE


                   HAEMACURE TO TAKE OVER HEMASEEL HMN PROJECT
                      WITH THE ASSISTANCE OF ZLB BIOPLASMA



Montreal, Quebec (Canada) March 13, 2002 - Haemacure Corporation today announced
a restructuring of its arrangements with ZLB Bioplasma AG, a wholly owned
subsidiary of CSL Limited (CSL) of Melbourne, Australia, whereby Haemacure will
take control of the manufacturing, clinical studies and registration efforts to
commercialize Haemacure's proprietary Hemaseel HMN technology. As part of the
new agreements, CSL Limited will fund a portion of Haemacure's efforts in return
for future royalties on Hemaseel HMN products.

In September 2000, CSL, a leading international plasma fractionator, acquired
the plasma fractionation business of the ZLB Central Laboratory of the Swiss Red
Cross (ZLB). CSL's acquisition required the integration of various ongoing
projects at the two companies, including ZLB's collaboration with Haemacure for
the manufacture and registration of Hemaseel HMN. At the same time, Haemacure
desired greater control over the direction of the Hemaseel HMN project and the
exploitation of commercial opportunities for this proprietary technology.
Accordingly, the parties agreed to terminate the previous agreements between
Haemacure and ZLB Bioplasma and enter into new arrangements.

Under the new agreements, Haemacure will take over responsibility for the
manufacturing of the Hemaseel HMN product, at a location to be determined, as
well as the clinical studies and registration of products based on the Hemaseel
HMN technology. In return for the transfer by ZLB Bioplasma to Haemacure of its
obligations under the previous agreements, and in order to assist Haemacure with
the project, Haemacure will receive the following:


A.     Cash payment of Can. $12.7 million consisting of:

          o      Can. $5.6 million at signature;
          o      Can. $1.5 million six (6) months after signature;
          o      Can. $5.6 million twelve (12) months after signature.

B.     Certain manufacturing/filling equipment suitable for the
       manufacture of Hemaseel HMN;

C.     ZLB Bioplasma documents related to the Hemaseel HMN project, and
       technical assistance for a period of up to 3 years;

D.     An exclusive, perpetual license to ZLB Bioplasma proprietary technology
       relating to the Hemaseel HMN project;


                                      - 2 -

E.     ZLB Bioplasma will fund additional activities at Haemacure upon the
       achievement of the following milestones relating to the initial
       Hemaseel HMN product:

       o      Can. $2.4 million upon commissioning of the new manufacturing
              facility;
       o      Can. $2.4 million upon approval of an Investigational New Drug
              application (IND) by the United States Food and Drug
              Administration;
       o      Can. $2.4 million upon achieving 50% of the target patient
              enrollment requirement directed by the regulatory authorities.

F.     ZLB Bioplasma will supply to HAE up to 50,000 liters of human plasma
       at cost through the launch of Hemaseel HMN.


In return for its assistance with this project, ZLB Bioplasma will receive a
three percent royalty on all net revenues received by Haemacure on sales of the
initial Hemaseel HMN product for ten years from the date of approval.

The Hemaseel HMN Technology consists of two processes (covered by four Haemacure
patents) to extract and purify fibrinogen and thrombin from human plasma. When
combined, both proteins produce a fibrin sealant known as Hemaseel HMN. The
Hemaseel HMN product has been subject to various clinical trials over the past
three years demonstrating the efficacy and safety of the product. Under the
previous agreement with ZLB, this technology had been fully developed and is now
ready for full scale production.

"This is a significant event for Haemacure," said Haemacure President and CEO
Marc Paquin. "The new arrangement allows us to control our own destiny in
commercializing the Hemaseel HMN Technology, with the financial and technical
assistance of a world-class plasma fractionator. This also allows ZLB Bioplasma
to concentrate on its core projects. It is a win-win for both parties."

An additional benefit of the new agreements is that Haemacure gets back
exclusive worldwide manufacturing and marketing rights to the Hemaseel HMN
technology. Under the previous agreements with ZLB, ZLB had worldwide
co-manufacturing and marketing rights for Hemaseel HMN products.

"We see a bright future for the Hemaseel HMN technology," added Wayne Johnson,
Chief Operating Officer of Haemacure. "Because Hemaseel HMN is an all-human
product and easier to reconstitute than current technologies, it will be
well-positioned to compete as a second-generation product." In addition, any
future manufacturing facility will include the ability for Haemacure to make
stand-alone fibrinogen and thrombin from the Hemaseel HMN technology.

Haemacure management is currently analyzing its manufacturing alternatives,
including an additional collaboration with its manufacturing partner for the
Hemaseel APR technology, BioProducts Laboratory, in Elstree, England, as well as
the possibility to build a new dedicated facility in Montreal, Canada. "We will
make an announcement in the next 45 - 60 days regarding the facility location."
said Mr. Paquin. Haemacure believes it can obtain Canadian, European and U.S.
approval for Hemaseel HMN in 2005.


                                     - 3 -

To provide further explanation to the content of this press release, the senior
management of Haemacure will hold a conference call on Wednesday, March 13, 2002
at 4:00 PM EST. To attend this conference dial in to 1-888-942-8173.

Haemacure Corporation is a Canada-based company specialized in the development
and commercialization of innovative biological adhesives, biomaterials and
surgical devices for the acute surgical wound care market. It also operates
sales and marketing, clinical and regulatory offices in Sarasota, Florida
through a wholly-owned subsidiary. The company is traded under stock symbol
TSE:HAE on the Toronto Stock Exchange. The Company is a reporting company with
the U.S. Securities Exchange Commission.

All dollar amounts set forth in this press release are in Canadian dollars,
except where otherwise stated.

Statements contained in this press release that are not historical facts are
forward-looking statements that are made pursuant to the safe harbor provisions
of the Private Securities and Litigation Reform Act of 1995 (United States). In
addition, words such as "believes," "anticipates," "expects" and similar
expressions are intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks, uncertainties or
other factors that may cause actual results, performance or achievements of the
Company to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Factors
that might cause such a difference include, but are not limited to, acceptance
of the Company's products by medical professionals, the ability of the Company
to continue to develop products, the completion of the BPL manufacturing
facility, the effect of competition, and any other risks described from time to
time in the Company's filings with the U.S. Securities and Exchange Commission.
Forward-looking statements in this release represent the Company's judgment as
of the date of this release. The Company disclaims, however, any intent or
obligation to update these forward-looking statements.

                                     - 30 -


Source:                             HAEMACURE CORPORATION

Toronto Stock Exchange:             TSE:HAE

Contacts:

  Mr. Marc Paquin           Mr. James Roberts            Mr. Clement Gagnon
  President and CEO         VP Finance & Admin., CFO     President
  Haemacure Corporation     Haemacure Corporation        CGE Communication Group
  Tel.: (941) 364-3700      Tel.: (941) 364-3700         Tel.: (514) 987-1455